Target Price | €9.16 |
Price | €3.20 |
Potential |
185.96%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Valneva 2025 .
The average Valneva target price is €9.16.
This is
185.96%
register free of charge
€12.14
279.01%
register free of charge
€3.90
21.80%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend Valneva to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Valneva stock has an average upside potential 2025 of
185.96%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million € | 153.71 | 177.53 |
57.46% | 15.50% | |
EBITDA Margin | -56.27% | 26.77% |
93.97% | 147.57% | |
Net Margin | -65.91% | -3.27% |
38.38% | 95.04% |
8 Analysts have issued a sales forecast Valneva 2024 . The average Valneva sales estimate is
This results in the following potential growth metrics:
2 Valneva Analysts have issued a net profit forecast 2024. The average Valneva net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share € | -0.73 | -0.04 |
41.13% | 94.52% | |
P/E | negative | |
EV/Sales | 2.71 |
2 Analysts have issued a Valneva forecast for earnings per share. The average Valneva <a href=/blog/eps>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Valneva stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.